Medtronic short-term struggles

What happened: Medtronic (MDT), a medical device manufacturer, faced a short-term setback. An analyst lowered MDT's price target by $15, citing concerns about its share price performance. Despite this, MDT remains a high-yielding stock, offering a 3.59% annual dividend. Meanwhile, Jim Cramer noted MDT's recent underperformance, stating it had become a "short-term loser" after being a "long-term winner". However, MDT's Q4 earnings showed a rise in its bottom line, with adjusted earnings per share increasing to $1.24 billion, or $0.96 per share, compared to $1.05 billion, or $0.82 per share, in the prior year.

Market impact: The medical device sector and healthcare investors are affected. The analyst's price target reduction and Cramer's comments may trigger profit-taking or selling, impacting MDT's share price. However, the strong Q4 earnings could attract investors seeking stable, dividend-paying stocks in the healthcare sector.

What to watch next: Medtronic's Q1 earnings release, scheduled for August 24, will provide further insight into the company's performance. Additionally, any updates on MDT's pipeline products and regulatory approvals, such as its recently launched HeartLogic Heart Failure Diagnostic Service, will be crucial to monitor. Lastly, changes in MDT's share price and trading volume around these events will indicate investor sentiment towards the company.